BioLife Solutions, Inc. · NASDAQ:BLFS
BioLife Solutions — Investor Presentation (May 2012)
18 slides from BioLife Solutions's investor presentation, May 2012
Slide 1: Investor Presentation May 2012
OTCBB: BLFS Investor Presentation May 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements about BioLife Solutions, Inc. (the “Company”) and its future operating results, strategies, and product dev
Slide 3: Leading Innovator Serving $500M Market
Leading Innovator Serving $500M Market NEXT- SCALABLE LARGE, GENERATION PRODUCTION GROWING PRODUCTS FACILITY CUSTOMER BASE Proprietary, best-in-class $25MM annual 300+ customers biopreserveratio revenue and key n media products capacity in a distributors in for cells, tissues scalable GMP strategic
Slide 4: Products and Services
Products and Services HypoThermo CryoStor BloodSto Contract sol® Cordr blood ® ® aseptic Cryopreservatio Hypothermic n freeze media stem cell media storage & formulation shipping media freeze media , fill and cGMP, Serum-free, protein-free finish biopreservation media products for services cells, ti
Slide 5: Target Markets
Target Markets Commercial cell therapy and Regenerativ tissue engineering companies, e Medicine hospital based stem cell transplant centers, university- based research labs Umbilical cord blood banks, ABiobanking adult stem cell banks, tissue banks, biorepositories Drug Pharmaceutical companies, cel
Slide 6: Regenerative Medicine Opportunity
Regenerative Medicine Opportunity Fragile, live cells from source materials such as blood, tissue, and organs are enabling the development of biologic-based therapies and treatments for the leading causes of death and disability. These must be transported from the processing lab to the bedside in a
Slide 7: BioLife Products Meet The Opportunity
BioLife Products Meet The Opportunity Pre-formulated cGMP Serum-free Protein-free Enable 2x to 3x longer shelf-life of cell and tissue-based clinical therapies – several days! Increase the yield and viability of cells in the clinical dose 7 2012 INVESTOR PRESENTATION 5- CONFIDENTIAL AND PR
Slide 8: CryoStor & HypoThermosol In Customer Clinical Trials
CryoStor® & HypoThermosol® In Customer Clinical Trials Any successful commercial application could result in $1-2M revenue per year Stroke Multiple Sclerosis Amyotrophic Lateral Age-related Macular Sclerosis Degeneration Myocardial Dilated Cardiomyopathy infarction Hematologic malignancies Chronic H
Slide 9: Rapidly Expanding Market
Rapidly Expanding Market Demand for Regenerative Medicine Biopreservation Market Growth (Billions) Media (Millions) $10 $550 $9 $500 $32B $500 $500M $8 $450 $7 $400 $6 $5.6 $350 $5 $300 $4 $250 $3 $200 $2 $150 $1.0 $150 $150 $1 $7B $100 M $0 $50 2011 2018 2011 2018 Source: VisionGain Source: Managem
Slide 10: Revenue Model Key to Record Growth
Revenue Model Key to Record Growth REVENUE STREAMS HIGHLIGHTS Regnerati Drug 2011 Revenue $2.8MM ve Discovery Medicine Customers 400+ Countries 50+ Distribut Biobank Employees 16 ors ing Patents 7 Contract Mfg 10 2012 INVESTOR PRESENTATION
Slide 11: Growth Trends
Growth Trends Record Sequential Revenue (000’s) $850 $800 $750 $700 $650 $600 $550 $500 $450 $400 Q1 2010 Q2 2010 Q3 2010 Q4 2010 Q1 2011 Q2 2011 Q3 2011 Q4 2011 Q1 2012 11 2012 INVESTOR PRESENTATION
Slide 12: Why Our Products Are In High Demand
Why Our Products Are In High Demand BioLife Preserved Cells Outperform all other biopreservation media Highest quality - GMP Competitive Products Customer service 12 2012 INVESTOR PRESENTATION
Slide 13: Competition
Competition Home-Brew Biopreservation Media Traditional, culture media-based formulas Separate components sourced from multiple vendors Mixing required for each daily/weekly batch Components typically not USP quality Limited release criteria and not for every batch Non-GMP process Limited biopreserv
Slide 14: How Our Products Are Different
How Our Products Are Different BioLife Biopreservation Media Advantages Proprietary formula, optimized to protect cells from low temperature stress Mitigates apoptosis & necrosis Free radical scavengers Energy substrates pH buffers Pre-Formulated – no mixing required cGMP manufactured USP or highest
Slide 15: Industry Leading Customers
Industry Leading Customers Drug Regenerative Biobanking Distributors Discovery Medicine 15 2012 INVESTOR PRESENTATION
Slide 16: Proprietary, High-Value Technology
Proprietary, High-Value Technology INTELLECTUAL PROPERTY EMBEDDED TECHNOLOGY 7 issued patents Critical supplier status with 5 submitted applications leading companies: Over 200 third-party Regenerative medicine issued and pending Cord blood banks patents citing BioLife Suppliers of cells
Slide 17: Investment Summary
Investment Summary Innovative Positioned for Operational Growth Plan Leader Growth Excellence • Best-in-class, • BioLife • High-quality, • Annual proprietary, technology is scalable GMP revenue first-choice embedded in manufacturing growth of 50% market numerous facility position current & • Moving
Slide 18: OTCBB: BLFS
OTCBB: BLFS http:// biolifesolutions.com